Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Plastic Antibodies Target Peptide

Nanotechnology: Molecularly imprinted nanoparticles remove bee toxin from blood

by Celia Henry Arnaud
May 5, 2010 | A version of this story appeared in Volume 88, Issue 19

TARGETED TOXIN
[+]Enlarge
Credit: Courtesy of Kenneth Shea
In this fluorescence image of the biodistribution of melittin and MIP nanoparticles in a mouse, the complex accumulates in the liver. Blue is the lowest level and red is the highest.
Credit: Courtesy of Kenneth Shea
In this fluorescence image of the biodistribution of melittin and MIP nanoparticles in a mouse, the complex accumulates in the liver. Blue is the lowest level and red is the highest.

Molecularly imprinted polymeric (MIP) nanoparticles can act as "plastic antibodies" to neutralize toxins in live animals, according to a new study (J. Am. Chem. Soc., DOI: 10.1021/ja102148f).

Chemists Kenneth J. Shea and Yu Hoshino of the University of California, Irvine, and coworkers developed MIP nanoparticles that target the peptide melittin, a component of bee venom that breaks open cells and causes them to release their contents. At high enough doses, melittin can lead to kidney failure and death.

The researchers make the nanoparticles by polymerizing various acrylamide monomers in the presence of melittin and then removing the template, creating binding sites for the target molecule. The approach is called molecular imprinting.

The Irvine team, working with the group of Naoto Oku at the University of Shizuoka, in Japan, injected a lethal dose of melittin into mice. Animals that then immediately received an injection of the melittin-targeting MIP nanoparticles showed a significantly higher survival rate than those that did not receive the nanoparticles. Although the MIP nanoparticles have previously been shown to target melittin in vitro with an affinity and selectivity comparable with those of natural antibodies (J. Am. Chem. Soc. 2008, 130, 15242), this is the first time the synthetic antibodies have been used in living animals.

"This is an excellent demonstration of the potential for molecularly imprinted nanoparticles to selectively bind peptides and related targets in the complex environment found in the bloodstream," says Steven C. Zimmerman of the University of Illinois, Urbana-Champaign, who also studies synthetic antibodies.

The nanoparticles show minimal toxicity, Shea says. The researchers determined the biodistribution of both the melittin and the MIP nanoparticles by fluorescence imaging of dye-labeled nanoparticles and melittin. The MIP nanoparticles and their targeted melittin accumulated in the same cells in the liver, suggesting that the nanoparticles sequester the toxin and that the complex is then cleared from the body by the liver.

Such nanoparticles could be fabricated for a variety of targets, Shea says. "This opens the door to serious consideration for these nanoparticles in all applications where proteins are used," he adds.

Advertisement

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.